Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.
Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.
复制标题
DOI：
10.1007/s40142-013-0019-1
复制
发表时间：
2013-09-01
影响因子：
2.1
通讯作者：
Hou L
中科院分区：
文献类型：
--
作者：
Zhang W;Zheng Y;Hou L
个性化医疗有望根据患者的基因组成和临床变量（如性别、种族和暴露于环境刺激）来定制医疗护理。药物遗传学和药物基因组学研究的最新进展表明，药物对治疗性治疗的反应可能是一种受多种遗传和非遗传因素影响的复杂性状。识别分子靶标（例如，遗传变异）描绘药物反应的遗传基础可以帮助理解药物反应的复杂性。在过去的十年里，全基因组分析技术在遗传/表观遗传变异和基因表达方面取得了重大进展。作为一种无偏倚的、基于细胞的药物基因组学发现模型，HapMap淋巴母细胞样细胞系（LCL）在过去十年中积累了大量的全基因组分子靶点资源。本文综述了LCL模型在肿瘤药物基因组学研究中的应用进展，以说明系统生物学方法对药物基因组学发现的潜在影响。
Personalized medicine has the promise to tailor medical care based on the patient’s genetic make-up and clinical variables such as gender, race and exposure to environmental stimuli. Recent progress in pharmacogenetic and pharmacogenomic studies has suggested that drug response to therapeutic treatments is likely a complex trait influenced by a variety of genetic and non-genetic factors. Identifying molecular targets (e.g., genetic variants) delineating the genetic basis of drug response could help understand the complex nature of drug response. The last decade has witnessed significant advances in genome-wide profiling technologies for genetic/epigenetic variations and gene expression. As an unbiased, cell-based model for pharmacogenomic discovery, a tremendous resource of whole-genome molecular targets has been accumulated for the HapMap lymphoblastoid cell lines (LCLs) during the past decade. The current progress, particularly in cancer pharmacogenomics, using the LCL model was reviewed to illustrate the potential impact of systems biology approaches on pharmacogenomic discovery.